Engels

Researchers are evaluating the effectiveness and safety of two drugs, Ranquilon and Afobazole, in treating patients who have anxiety disorders due to neurasthenia and adjustment disorders. This is a Phase IV clinical study focusing on patients aged 18 to 70 years with specific anxiety levels and diagnoses confirmed by ICD-10 criteria. The study aims to compare the impact of these treatments on reducing anxiety symptoms. Participants will receive either Ranquilon tablets at a dose of 6 mg per day or Afobazole tablets at a dose of 30 mg per day. The study is open-label, comparative, randomized, and conducted at multiple centers. Treatment is administered orally, with dosing schedules guided by the study protocol. During the study, patients will be regularly assessed using the Hamilton Anxiety Rating Scale (HARS) to measure anxiety reduction, with the primary outcome being a 50% or greater decrease in anxiety levels by Day 29. Additional evaluations include safety monitoring and adherence checks. Participants provide informed consent and must comply with study procedures throughout the trial duration.

Researchers are evaluating the effectiveness, safety, and tolerability of the drug 4-MUST at different doses compared to a placebo in adults aged 18 to 70 years with chronic cholecystitis and biliary dyskinesia. This Phase 2 study focuses on patients experiencing pain or discomfort in the upper abdomen along with other digestive symptoms such as heartburn, nausea, bloating, or changes in bowel habits. The goal is to see how well 4-MUST reduces upper abdominal pain and improves gastrointestinal symptoms. Participants receive either 4-MUST tablets containing 128 mg of trimebutine 4-methylumbelliferyl sulfate or placebo tablets. The study compares various doses of 4-MUST to placebo in parallel groups under double-blind conditions, meaning neither doctors nor patients know which treatment is given. The treatments are administered over a period that allows assessment of pain relief and safety. During the study, participants will be assessed for changes in upper abdominal pain severity using a visual analog scale by day 29 compared to baseline. Researchers will monitor safety and tolerability through questionnaires and clinical evaluations. Women must use effective contraception or meet specific reproductive criteria, and all participants will provide informed consent. The study includes careful monitoring for compliance, adverse events, and other health conditions that might affect participation or outcomes.

Researchers are studying the quality of primary health care for patients with arterial hypertension, focusing on how timely, accessible, and modern the medical care is. The study aims to evaluate how well doctors follow current clinical recommendations for diagnosis and treatment. It uses a cardiovascular disease registry system established at a federal clinical hospital in Russia to analyze patient data and improve care practices. The study collects medical data from outpatient records of patients aged 18 to 99 years with diagnosed arterial hypertension. This information is entered into an arterial hypertension registry, a computer program with remote access designed for online data collection from primary care. Doctors were trained to minimize errors, and patient data is transmitted anonymously through a secure channel after informed consent is obtained. Participants' medical examination and treatment data will be analyzed to observe trends in care quality from 2018 to 2021. The main outcome measured is the number of patients achieving blood pressure below 140/90 mm Hg. The registry allows ongoing monitoring and comparison with clinical guidelines to identify areas for improvement in managing arterial hypertension.

Researchers are evaluating the effectiveness and safety of varying doses of Grammidin with anesthetic, a metered dose topical spray, in treating acute infectious and inflammatory diseases of the throat. This Phase 2 study compares Grammidin with anesthetic to Septolete Total lozenges in adults aged 18 to 75 who experience sore throat symptoms due to conditions like acute pharyngitis, nasopharyngitis, or exacerbation of chronic pharyngitis. Participants receive different doses of Grammidin with anesthetic spray or Septolete Total lozenges. The study involves a randomized, parallel-group design to compare these treatments. The primary measure of success combines pain intensity and throat assessment scores over the first 8 days of treatment, with visits scheduled accordingly. During the study, participants report sore throat severity using the Visual Analog Scale and other clinical symptom scales. Researchers monitor symptom changes from Day 1 to Day 8 and assess safety throughout. Patients must meet specific criteria such as symptom duration and pregnancy testing, and they are followed closely to measure treatment effects and any adverse events during this period.